Life Science Division, Tsinghua University Graduate School at Shenzhen, Shenzhen, China.
Stem Cell Rev Rep. 2012 Mar;8(1):243-50. doi: 10.1007/s12015-011-9293-z.
A growing body of preclinical evidence suggests that mesenchymal stem cells (MSCs) are effective for the structural and functional recovery of the infracted heart. Accordingly, clinical trials are underway to determine the benefit of MSC-based therapies. While systemic administration of MSCs is an attractive strategy, and is the route currently used for the administration of MSCs in clinical studies for myocardial infarction, the majority of infused cells do not appear to localize to infracted myocardium in animal studies. Recently, important progress has been made in identifying chemokine receptors critical for the migration and homing of MSCs. Here, we review recent literature regarding mechanisms of MSC homing and recruitment to the ischemic myocardium, and discuss potential influences of low engraftment rates of systemically administered MSCs to the infracted heart tissue on the effects of MSC-based therapies on myocardial infarction.
越来越多的临床前证据表明间充质干细胞（MSCs）可有效促进梗死心脏的结构和功能恢复。因此，正在进行临床试验以确定基于 MSC 的治疗方法的益处。虽然系统给予 MSC 是一种有吸引力的策略，也是目前在心肌梗死的临床研究中用于给予 MSC 的途径，但在动物研究中，大多数输注的细胞似乎不会定位于梗死的心肌。最近，在确定对 MSC 迁移和归巢至关重要的趋化因子受体方面取得了重要进展。在这里，我们回顾了有关 MSC 归巢和招募到缺血性心肌机制的最新文献，并讨论了系统给予的 MSC 低植入率对梗死心脏组织对基于 MSC 的治疗方法对心肌梗死影响的潜在影响。
